Eli Lilly and Company (NYSE: LLY), a global healthcare company, has dosed patients in the first study of LY-CoV555 intended to prevent COVID-19, it was reported on Monday.
The product has been developed as a result of the collaboration between Lilly and AbCellera. It is a potent, neutralising IgG1 monoclonal antibody directed against the SARS-CoV-2 spike protein. The first patients have been dosed at major medical centres in the United States, including NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles.
The firm aims to study the drug in a preventative setting, concentrating on vulnerable patient populations who historically are not optimal candidates for vaccines. Should Phase 1 results show the antibody can be safely administered, Lilly expects to move into the next phase of testing, studying LY-CoV555 in non-hospitalised COVID-19 patients.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine